Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2009;119:2408-2416
Published online before print April 13, 2009, doi: 10.1161/CIRCULATIONAHA.109.192278
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v119,pe606)
Right arrow All Versions of this Article:
119/17/2408    most recent
CIRCULATIONAHA.109.192278v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hlatky, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hlatky, M. A.
Related Collections
Right arrow Health policy and outcome research
Right arrow Primary prevention
Right arrow Risk Factors
Right arrow Other diagnostic testing
Right arrow Epidemiology

(Circulation. 2009;119:2408-2416.)
© 2009 American Heart Association, Inc.


AHA Scientific Statement

Criteria for Evaluation of Novel Markers of Cardiovascular Risk

A Scientific Statement From the American Heart Association

Mark A. Hlatky, MD, FAHA, Chair; Philip Greenland, MD, FAHA, Co-Chair; Donna K. Arnett, PhD, FAHA; Christie M. Ballantyne, MD; Michael H. Criqui, MD, FAHA; Mitchell S.V. Elkind, MD, MS; Alan S. Go, MD; Frank E. Harrell, Jr, PhD; Yuling Hong, MD, PhD, FAHA; Barbara V. Howard, PhD, FAHA; Virginia J. Howard, PhD, FAHA; Priscilla Y. Hsue, MD; Christopher M. Kramer, MD, FAHA; Joseph P. McConnell, PhD; Sharon-Lise T. Normand, PhD; Christopher J. O'Donnell, MD; Sidney C. Smith, Jr, MD, FAHA; Peter W.F. Wilson, MD, on behalf of the American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council

There is increasing interest in utilizing novel markers of cardiovascular disease risk, and consequently, there is a need to assess the value of their use. This scientific statement reviews current concepts of risk evaluation and proposes standards for the critical appraisal of risk assessment methods. An adequate evaluation of a novel risk marker requires a sound research design, a representative at-risk population, and an adequate number of outcome events. Studies of a novel marker should report the degree to which it adds to the prognostic information provided by standard risk markers. No single statistical measure provides all the information needed to assess a novel marker, so measures of both discrimination and accuracy should be reported. The clinical value of a marker should be assessed by its effect on patient management and outcomes. In general, a novel risk marker should be evaluated in several phases, including initial proof of concept, prospective validation in independent populations, documentation of incremental information when added to standard risk markers, assessment of effects on patient management and outcomes, and ultimately, cost-effectiveness.


Key Words: AHA Scientific Statements • risk assessment • models, statistical • evaluation studies




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
D. Bolliger, M. D. Seeberger, and M. Filipovic
Pre-operative cardiac risk assessment in noncardiac surgery: are natriuretic peptides the magic bullet?
J. Am. Coll. Cardiol., October 20, 2009; 54(17): 1607 - 1608.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome.
J. Am. Coll. Cardiol., October 13, 2009; 54(16): 1544 - 1555.
[Full Text] [PDF]


Home page
NEJMHome page
R. O. Bonow
Should Coronary Calcium Screening Be Used in Cardiovascular Prevention Strategies?
N. Engl. J. Med., September 3, 2009; 361(10): 990 - 997.
[Full Text] [PDF]


Home page
J Am Coll Cardiol ImgHome page
W.H. W. Tang
Enhancing the Prognostic Value of Cardiac Imaging With Multimodal Risk Assessment
J. Am. Coll. Cardiol. Img., September 1, 2009; 2(9): 1100 - 1102.
[Full Text] [PDF]


Home page
Circ Heart FailHome page
S. M. Dunlay, Y. Gerber, S. A. Weston, J. M. Killian, M. M. Redfield, and V. L. Roger
Prognostic Value of Biomarkers in Heart Failure: Application of Novel Methods in the Community
Circ Heart Fail, September 1, 2009; 2(5): 393 - 400.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
R. J. Gibbons and T. C. Gerber
Calcium Scoring With Computed Tomography: What Is the Radiation Risk?
Arch Intern Med, July 13, 2009; 169(13): 1185 - 1187.
[Full Text] [PDF]